Diligence memo · auto-generated · as of July 2, 2026
Trevarx Biomedical, Inc.
Trevarx Biomedical, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Trevarx Biomedical, Inc. operates in Biotechnology, based in PHILADELPHIA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Trevarx Biomedical, Inc. has raised $1.5M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $650K on 2019-07-24.
Most recent recorded round closed around 2025-07-25.
Valuation (modeled)modeled
Provath models Trevarx Biomedical, Inc. at approximately $834K (range $187K–$2.0M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.87× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (79 peers) — value vs value, same stage and era. Within the normal band (87% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 36 months.
Last raise 11 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 24% of Biotechnology peers (4293 compared).
Modeled value ranks above 2% of those peers.
Closest niche peers: Illexcor Holdings, LLC, Reprogram Biosciences, Inc., Maxymune Therapeutics, Inc., EnZeta Immunotherapies, Inc., Eliaz Therapeutics Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.